MedTrace Logo

Benefits of a Cannabidiolic Acid Topical Cream for the Treatment of Restless Leg Syndrome

NCT06570941 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-08-28

No results posted yet for this study

Summary

The goal of this open label clinical trial is to reduce the effects of restless leg syndrome. The main it questions it aims to answer are:

1. Reduce or eliminate the symptoms of restless leg syndrome.
2. Improve the quality of life of participants with restless leg syndrome.

Participants will be asked to apply the topical cream to the affected area 30 to 45 minutes before bedtime for 14 consecutive days.

Conditions

  • Restless Legs Syndrome

Interventions

DRUG

Chylobinoid Topical Cream

The topical cream is applied to the effected area to reduce or eliminate the symptoms of restless leg syndrome

Sponsors & Collaborators

  • Synthonics Inc

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-01
Primary Completion
2024-09-30
Completion
2024-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06570941 on ClinicalTrials.gov